

J Henricus Van Krieken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6273947/publications.pdf>

Version: 2024-02-01

165
papers

9,939
citations

71061

41
h-index

36008

97
g-index

167
all docs

167
docs citations

167
times ranked

15589
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 972-983. | 3.2 | 22 |
| 2 | Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , 2021, 19, 249-260. | 1.5 | 20 |
| 3 | e-Learning for Instruction and to Improve Reproducibility of Scoring Tumor-Stroma Ratio in Colon Carcinoma: Performance and Reproducibility Assessment in the UNITED Study. <i>JMIR Formative Research</i> , 2021, 5, e19408. | 0.7 | 9 |
| 4 | Daily practice in guideline adherence to adjuvant chemotherapy in stage III colon cancer and predictors of outcome. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2060-2068. | 0.5 | 3 |
| 5 | Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer: a cohort study. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2729-2737. | 1.0 | 8 |
| 6 | Memento for interprofessional learning. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 755-756. | 1.4 | 1 |
| 7 | High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites. <i>Blood</i> , 2019, 134, 946-950. | 0.6 | 18 |
| 8 | Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study. <i>Histopathology</i> , 2019, 75, 312-319. | 1.6 | 15 |
| 9 | Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study. <i>JMIR Research Protocols</i> , 2019, 8, e13464. | 0.5 | 20 |
| 10 | The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact. <i>Histopathology</i> , 2018, 73, 197-206. | 1.6 | 97 |
| 11 | External Quality Assessment Identifies Training Needs to Determine the Neoplastic Cell Content for Biomarker Testing. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 455-464. | 1.2 | 16 |
| 12 | RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 717-725. | 1.4 | 7 |
| 13 | Detection of EGFR Variants in Plasma. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 483-494. | 1.2 | 37 |
| 14 | Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. <i>Leukemia</i> , 2018, 32, 353-363. | 3.3 | 36 |
| 15 | Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 405-412. | 1.4 | 113 |
| 16 | Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018, 20, 574-593. | 2.3 | 64 |
| 17 | A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. <i>Modern Pathology</i> , 2018, 31, 1770-1786. | 2.9 | 739 |
| 18 | Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories. <i>British Journal of Cancer</i> , 2018, 119, 605-614. | 2.9 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Recurrent mutations in genes involved in nuclear factor- κ B signalling in nodal marginal zone lymphoma—diagnostic and therapeutic implications. <i>Histopathology</i> , 2017, 70, 174-184. | 1.6 | 21 |
| 20 | AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2017, 187, 1700-1716. | 1.9 | 39 |
| 21 | Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations. <i>British Journal of Cancer</i> , 2017, 117, 1685-1688. | 2.9 | 13 |
| 22 | Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma. <i>Journal of Hematopathology</i> , 2017, 10, 91-107. | 0.2 | 45 |
| 23 | New developments in the pathology of malignant lymphoma: a review of the literature published from May to August 2017. <i>Journal of Hematopathology</i> , 2017, 10, 65-73. | 0.2 | 8 |
| 24 | Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. <i>European Journal of Human Genetics</i> , 2017, 25, 1246-1252. | 1.4 | 34 |
| 25 | Quality in pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 311-312. | 1.4 | 0 |
| 26 | New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2017. <i>Journal of Hematopathology</i> , 2017, 10, 25-33. | 0.2 | 3 |
| 27 | Will the liquid biopsy replace traditional hematopathology?. <i>Journal of Hematopathology</i> , 2017, 10, 1-1. | 0.2 | 0 |
| 28 | <i>RAS</i> mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data. <i>Biomarkers in Medicine</i> , 2017, 11, 751-760. | 0.6 | 33 |
| 29 | Pathways towards indolent B-cell lymphoma — Etiology and therapeutic strategies. <i>Blood Reviews</i> , 2017, 31, 426-435. | 2.8 | 7 |
| 30 | Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma. <i>Histopathology</i> , 2017, 70, 643-649. | 1.6 | 14 |
| 31 | Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. <i>Leukemia</i> , 2017, 31, 625-636. | 3.3 | 47 |
| 32 | Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 5-20. | 1.4 | 82 |
| 33 | Targeting the environment. <i>Journal of Hematopathology</i> , 2017, 10, 47-47. | 0.2 | 0 |
| 34 | New developments in the pathology of malignant lymphoma. A review of the literature published from September—August 2017. <i>Journal of Hematopathology</i> , 2017, 10, 117-127. | 0.2 | 3 |
| 35 | Editorial: when to be an author?. <i>Journal of Hematopathology</i> , 2017, 10, 89-90. | 0.2 | 1 |
| 36 | High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients. <i>PLoS ONE</i> , 2017, 12, e0185607. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. <i>Oncotarget</i> , 2017, 8, 54434-54443. | 0.8 | 13 |
| 38 | Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 2401-2416. | 0.8 | 93 |
| 39 | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422. | 0.6 | 2,545 |
| 40 | Are we making progress?. <i>Journal of Hematopathology</i> , 2016, 9, 51-51. | 0.2 | 1 |
| 41 | Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016. <i>ESMO Open</i> , 2016, 1, e000114. | 2.0 | 6 |
| 42 | Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 3593-3605. | 3.2 | 48 |
| 43 | The Role of Dectin-2 for Host Defense Against Disseminated Candidiasis. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 267-276. | 0.5 | 45 |
| 44 | T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. <i>Cancer Research</i> , 2016, 76, 3496-3506. | 0.4 | 33 |
| 45 | New developments in the pathology of malignant lymphoma. A review of the literature published from Januaryâ€“April 2016. <i>Journal of Hematopathology</i> , 2016, 9, 73-83. | 0.2 | 3 |
| 46 | Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. <i>Advances in Experimental Medicine and Biology</i> , 2016, 908, 371-391. | 0.8 | 47 |
| 47 | New developments in the pathology of malignant lymphoma: a review of the literature published from Juneâ€“August 2016. <i>Journal of Hematopathology</i> , 2016, 9, 129-134. | 0.2 | 2 |
| 48 | Open access and data. <i>Journal of Hematopathology</i> , 2016, 9, 105-105. | 0.2 | 0 |
| 49 | We need to be (much) better. <i>Journal of Hematopathology</i> , 2016, 9, 1-1. | 0.2 | 0 |
| 50 | How we do: optimizing bone marrow biopsy logistics for sign-out within 2Âˆdays. <i>Journal of Hematopathology</i> , 2016, 9, 67-71. | 0.2 | 2 |
| 51 | New developments in the pathology of malignant lymphoma. A review of the literature published from September 2015â€“December 2015. <i>Journal of Hematopathology</i> , 2016, 9, 19-27. | 0.2 | 3 |
| 52 | Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation. <i>Leukemia and Lymphoma</i> , 2016, 57, 1649-1656. | 0.6 | 13 |
| 53 | RAS testing in metastatic colorectal cancer: advances in Europe. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 383-396. | 1.4 | 27 |
| 54 | A 20-year population-based study on the epidemiology, clinical features, treatment, and outcome of nodular lymphocyte predominant Hodgkin lymphoma. <i>Annals of Hematology</i> , 2016, 95, 417-423. | 0.8 | 18 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 205-214. | 1.2 | 23 |
| 56 | A subset of low-grade B cell lymphomas with a follicular growth pattern but without a BCL2 translocation shows features suggestive of nodal marginal zone lymphoma. <i>Journal of Hematopathology</i> , 2016, 9, 3-8. | 0.2 | 7 |
| 57 | Tetraspanin CD37 protects against the development of B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 653-666. | 3.9 | 47 |
| 58 | p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. <i>Aging</i> , 2016, 8, 345-365. | 1.4 | 19 |
| 59 | RelA NF- κ B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016, 8, 3321-3340. | 1.4 | 29 |
| 60 | Improving hospital care for patients with non-Hodgkin's lymphomas.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6593-6593. | 0.8 | 0 |
| 61 | Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disorders. <i>Haematologica</i> , 2015, 100, e152-e154. | 1.7 | 2 |
| 62 | The folly of impact factors: some solutions. <i>Journal of Hematopathology</i> , 2015, 8, 49-49. | 0.2 | 0 |
| 63 | We are not our genes. <i>Journal of Hematopathology</i> , 2015, 8, 201-202. | 0.2 | 0 |
| 64 | Reduced Circumferential Resection Margin Involvement in Rectal Cancer Surgery: Results of the Dutch Surgical Colorectal Audit. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1111-1119. | 2.3 | 19 |
| 65 | Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review. <i>PLoS ONE</i> , 2015, 10, e0140717. | 1.1 | 9 |
| 66 | Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 5597-5614. | 0.8 | 61 |
| 67 | New developments in the pathology of malignant lymphoma: a review of the literature published from May 2015â€“September 2015. <i>Journal of Hematopathology</i> , 2015, 8, 225-234. | 0.2 | 2 |
| 68 | Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma - combined performance of multiple markers. <i>Haematologica</i> , 2015, 100, e358-e360. | 1.7 | 20 |
| 69 | Gastric cancer in three relatives of a patient with a biallelic IL12RB1 mutation. <i>Familial Cancer</i> , 2015, 14, 89-94. | 0.9 | 14 |
| 70 | Epsteinâ€“Barr Virus in Inflammatory Bowel Disease: The Spectrum of Intestinal Lymphoproliferative Disorders. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 398-403. | 0.6 | 70 |
| 71 | Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers. <i>Journal of Medical Genetics</i> , 2015, 52, 361-374. | 1.5 | 479 |
| 72 | Trends in quality of non-Hodgkinâ€™s lymphoma care: is it getting better?. <i>Annals of Hematology</i> , 2015, 94, 1195-1203. | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | The folly of impact factors. <i>Journal of Hematopathology</i> , 2015, 8, 1-1. | 0.2 | 0 |
| 74 | A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. <i>Nature Genetics</i> , 2015, 47, 668-671. | 9.4 | 311 |
| 75 | New developments in the pathology of malignant lymphoma: a review of the literature published from October 2014–December 2014. <i>Journal of Hematopathology</i> , 2015, 8, 21-29. | 0.2 | 1 |
| 76 | New developments in the pathology of malignant lymphoma: a review of literature published from January 2015 to April 2015. <i>Journal of Hematopathology</i> , 2015, 8, 71-79. | 0.2 | 2 |
| 77 | Variation in guideline adherence in non-Hodgkin's lymphoma care: impact of patient and hospital characteristics. <i>BMC Cancer</i> , 2015, 15, 578. | 1.1 | 6 |
| 78 | Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015, 28, 1555-1573. | 2.9 | 48 |
| 79 | Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015, 28, 1297-1314. | 2.9 | 21 |
| 80 | The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 273-278. | 1.4 | 11 |
| 81 | Paediatric hematopathology: something real special. <i>Journal of Hematopathology</i> , 2015, 8, 99-99. | 0.2 | 0 |
| 82 | Immunoglobulin rearrangement analysis from multiple lesions in the same patient using next-generation sequencing. <i>Histopathology</i> , 2015, 67, 843-858. | 1.6 | 5 |
| 83 | Evaluation of NF- κ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , 2015, 28, 1202-1213. | 2.9 | 17 |
| 84 | Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1891-1894. | 0.6 | 14 |
| 85 | External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer. <i>Oncologist</i> , 2015, 20, 257-262. | 1.9 | 39 |
| 86 | Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , 2015, 6, 5615-5633. | 0.8 | 72 |
| 87 | RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers. <i>Oncotarget</i> , 2015, 6, 15681-15689. | 0.8 | 12 |
| 88 | Prognostic impact of c-Rel nuclear expression and <i>REL</i> amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 23157-23180. | 0.8 | 35 |
| 89 | Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. <i>Oncotarget</i> , 2015, 6, 13933-13945. | 0.8 | 33 |
| 90 | Awareness of KRAS testing by oncologists and panitumumab use in colorectal cancer patients: A European survey.. <i>Journal of Clinical Oncology</i> , 2015, 33, 547-547. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | New developments in the pathology of malignant lymphoma. A review of the literature published from June–August 2014. <i>Journal of Hematopathology</i> , 2014, 7, 103-108. | 0.2 | 0 |
| 92 | Lymphomas in Istanbul. <i>Journal of Hematopathology</i> , 2014, 7, 145-145. | 0.2 | 0 |
| 93 | Evaluation of a panel of expert pathologists: review of the diagnosis and histological classification of Hodgkin and non-Hodgkin lymphomas in a population-based cancer registry. <i>Leukemia and Lymphoma</i> , 2014, 55, 1018-1022. | 0.6 | 11 |
| 94 | New and old questions. <i>Journal of Hematopathology</i> , 2014, 7, 93-93. | 0.2 | 0 |
| 95 | Role of Dectin-2 for Host Defense against Systemic Infection with <i>Candida glabrata</i> . <i>Infection and Immunity</i> , 2014, 82, 1064-1073. | 1.0 | 100 |
| 96 | Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments. <i>Neoplasia</i> , 2014, 16, 221-228. | 2.3 | 18 |
| 97 | Editorial for the <i>Journal of Hematopathology</i> : crisis in science?. <i>Journal of Hematopathology</i> , 2014, 7, 1-1. | 0.2 | 0 |
| 98 | New developments in the pathology of malignant lymphoma. A review of the literature published from August 2013 to December 2013. <i>Journal of Hematopathology</i> , 2014, 7, 15-25. | 0.2 | 0 |
| 99 | Sequential immunohistochemistry: a promising new tool for the pathology laboratory. <i>Histopathology</i> , 2014, 65, 651-657. | 1.6 | 44 |
| 100 | Prevalence and Clinical Implications of Epstein–Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries. <i>Clinical Cancer Research</i> , 2014, 20, 2338-2349. | 3.2 | 117 |
| 101 | Grey zone lymphomas. <i>Journal of Hematopathology</i> , 2014, 7, 47-47. | 0.2 | 0 |
| 102 | HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 673-679. | 1.4 | 26 |
| 103 | Limited diagnostic value of microsatellite instability associated pathology features in colorectal cancer. <i>Familial Cancer</i> , 2014, 13, 351-359. | 0.9 | 3 |
| 104 | Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2014, 27, 958-971. | 2.9 | 112 |
| 105 | Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 5113-5123. | 3.2 | 60 |
| 106 | Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Cancer</i> , 2014, 120, 1818-1829. | 2.0 | 32 |
| 107 | Higher Quality of Molecular Testing, an Unfulfilled Priority. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 371-377. | 1.2 | 22 |
| 108 | To publish or perish. <i>Journal of Hematopathology</i> , 2013, 6, 55-55. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Precision medicine. <i>Journal of Hematopathology</i> , 2013, 6, 1-1. | 0.2 | 3 |
| 110 | The ileo neo rectal anastomosis: long-term results of surgical innovation in patients after ulcerative colitis and familial adenomatous polyposis. <i>International Journal of Colorectal Disease</i> , 2013, 28, 111-118. | 1.0 | 5 |
| 111 | Cancer, or not. <i>Journal of Hematopathology</i> , 2013, 6, 119-119. | 0.2 | 0 |
| 112 | Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites. <i>Leukemia and Lymphoma</i> , 2013, 54, 1891-1897. | 0.6 | 17 |
| 113 | Guideline on the requirements of external quality assessment programs in molecular pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 27-37. | 1.4 | 70 |
| 114 | KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 39-46. | 1.4 | 26 |
| 115 | MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031. | 0.6 | 596 |
| 116 | CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724. | 0.6 | 206 |
| 117 | The evaluation of colon biopsies using virtual microscopy is reliable. <i>Histopathology</i> , 2013, 63, 114-121. | 1.6 | 23 |
| 118 | Diagnosing and classifying malignant lymphomas is improved by referring cases to a panel of expert pathologists. <i>Journal of Hematopathology</i> , 2013, 6, 179-185. | 0.2 | 1 |
| 119 | Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. <i>Haematologica</i> , 2013, 98, 255-263. | 1.7 | 142 |
| 120 | Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review. <i>Haematologica</i> , 2013, 98, 1003-1013. | 1.7 | 85 |
| 121 | T(14;18)(q32;q21) involving MALT1 and IGH genes occurs in extranodal diffuse large B-cell lymphomas of the breast and testis. <i>Modern Pathology</i> , 2013, 26, 421-427. | 2.9 | 20 |
| 122 | European Consensus Conference for external quality assessment in molecular pathology. <i>Annals of Oncology</i> , 2013, 24, 1958-1963. | 0.6 | 39 |
| 123 | Undertreatment of patients with localized extranodal compared with nodal diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1698-1705. | 0.6 | 7 |
| 124 | Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4529-4540. | 0.6 | 41 |
| 125 | What we talk about when we talk about T-cell lymphomas. <i>Journal of Hematopathology</i> , 2012, 5, 289-289. | 0.2 | 0 |
| 126 | Centralised multidisciplinary re-evaluation of diagnostic procedures in patients with newly diagnosed Hodgkin lymphoma. <i>Annals of Oncology</i> , 2012, 23, 2676-2681. | 0.6 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 425-431. | 1.4 | 4 |
| 128 | Application of Microfluidic Technology to the BIOMED-2 Protocol for Detection of B-Cell Clonality. Journal of Molecular Diagnostics, 2012, 14, 30-37. | 1.2 | 21 |
| 129 | Do Pre-Analytical Parameters Explain KRAS Test Sensitivity Disparities?. Journal of Molecular Diagnostics, 2012, 14, 631-633. | 1.2 | 2 |
| 130 | Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia, 2012, 26, 2103-2113. | 3.3 | 301 |
| 131 | Welcome to Lisbon!. Journal of Hematopathology, 2012, 5, 105-105. | 0.2 | 0 |
| 132 | New developments in the pathology of malignant lymphoma. A review of the literature published from January 2012â€“July 2012. Journal of Hematopathology, 2012, 5, 149-157. | 0.2 | 0 |
| 133 | Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Familial Cancer, 2012, 11, 363-369. | 0.9 | 71 |
| 134 | Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. Leukemia and Lymphoma, 2012, 53, 242-246. | 0.6 | 14 |
| 135 | Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type. Leukemia and Lymphoma, 2012, 53, 1032-1045. | 0.6 | 18 |
| 136 | Implementation of Formalin-Fixed, Paraffin-Embedded Cell Line Pellets as High-Quality Process Controls in Quality Assessment Programs for KRAS Mutation Analysis. Journal of Molecular Diagnostics, 2012, 14, 187-191. | 1.2 | 13 |
| 137 | <i>CDH1</i> -related hereditary diffuse gastric cancer syndrome: Clinical variations and implications for counseling. International Journal of Cancer, 2012, 131, 367-376. | 2.3 | 110 |
| 138 | Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologistâ€™s initiative. Familial Cancer, 2012, 11, 259-267. | 0.9 | 16 |
| 139 | A practical approach to diagnostic Ig/TCR clonality evaluation in clinical pathology. Journal of Hematopathology, 2012, 5, 17-25. | 0.2 | 12 |
| 140 | Editorial: the second special issue of the Journal of Hematopathology. Journal of Hematopathology, 2012, 5, 1-1. | 0.2 | 0 |
| 141 | Clonality testing: teamwork by pathologist and molecular biologist. Journal of Hematopathology, 2012, 5, 3-5. | 0.2 | 0 |
| 142 | The times have changed: molecular pathology is here to stay. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 129-130. | 1.4 | 3 |
| 143 | Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncology, The, 2011, 12, 49-55. | 5.1 | 232 |
| 144 | Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. Histopathology, 2011, 59, 1-7. | 1.6 | 44 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Inter-observer variation in the histological diagnosis of polyps in colorectal cancer screening. <i>Histopathology</i> , 2011, 58, 974-981. | 1.6 | 46 |
| 146 | Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. <i>European Journal of Human Genetics</i> , 2011, 19, 870-874. | 1.4 | 141 |
| 147 | KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. <i>British Journal of Cancer</i> , 2011, 104, 1020-1026. | 2.9 | 262 |
| 148 | Variation in Lymph Node Evaluation in Rectal Cancer: A Dutch Nationwide Population-Based Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 386-395. | 0.7 | 21 |
| 149 | Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 155-160. | 1.4 | 18 |
| 150 | The times they are a-changin'. <i>Journal of Hematopathology</i> , 2011, 4, 1-1. | 0.2 | 0 |
| 151 | New developments in the pathology of malignant lymphoma: a review of the literature published from November 2010 to January 2011. <i>Journal of Hematopathology</i> , 2011, 4, 31-43. | 0.2 | 0 |
| 152 | High prevalence of adverse prognostic genetic aberrations and unmutated IGHV genes in small lymphocytic lymphoma as compared to chronic lymphocytic leukemia. <i>Journal of Hematopathology</i> , 2011, 4, 189-197. | 0.2 | 2 |
| 153 | Crisis? What crisis?. <i>Journal of Hematopathology</i> , 2011, 4, 133-133. | 0.2 | 0 |
| 154 | New developments in the pathology of malignant lymphoma. A review of the literature published from February 2011 to August 2011. <i>Journal of Hematopathology</i> , 2011, 4, 135-144. | 0.2 | 0 |
| 155 | Rising costs of health care and pathology: cause or solution?. <i>Journal of Hematopathology</i> , 2011, 4, 185-185. | 0.2 | 0 |
| 156 | Recurrence and variability of germline <i>EPCAM</i> deletions in Lynch syndrome. <i>Human Mutation</i> , 2011, 32, 407-414. | 1.1 | 137 |
| 157 | Identification of candidate predisposing copy number variants in familial and early-onset colorectal cancer patients. <i>International Journal of Cancer</i> , 2011, 129, 1635-1642. | 2.3 | 66 |
| 158 | Cellular angiofibroma: analysis of 25 cases emphasizing its relationship to spindle cell lipoma and mammary-type myofibroblastoma. <i>Modern Pathology</i> , 2011, 24, 82-89. | 2.9 | 159 |
| 159 | External Quality Assessment for <i>KRAS</i> Testing Is Needed: Setup of a European Program and Report of the First Jointed Regional Quality Assessment Rounds. <i>Oncologist</i> , 2011, 16, 467-478. | 1.9 | 83 |
| 160 | Large variation between hospitals and pathology laboratories in lymph node evaluation in colon cancer and its impact on survival, a nationwide population-based study in The Netherlands. <i>Annals of Oncology</i> , 2011, 22, 110-117. | 0.6 | 39 |
| 161 | Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 3100-3108. | 3.9 | 271 |
| 162 | Overlap, Common Features, and Essential Differences in Pediatric Granulomatous Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2010, 51, 690-697. | 0.9 | 56 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Are we making progress?. Journal of Hematopathology, 2010, 3, 59-59. | 0.2 | 0 |
| 164 | New developments in the pathology of malignant lymphoma. A review of the literature published from August 2010â€“October 2010. Journal of Hematopathology, 2010, 3, 167-174. | 0.2 | 0 |
| 165 | Use of RNA Electroporated DC for Activation of LRH-1 Specific Cytotoxic T Lymphocytes in the Treatment of Lymphoid Malignancies.. Blood, 2006, 108, 138-138. | 0.6 | 1 |